EUVIMEDEUVIMED entdecken
Crossref

AB011. Clinicopathological characteristics of thymic neuroendocrine tumors from the French RYTHMIC Network: focus on the newly defined G3 subtype

Lara Chalabreysse, Alexandre Megherbi, Véronique Hofman, Jérome Cros, Damien Sizaret, Alice Millière, Vincent de Montpreville, Nicolas Piton, Romain Dubois, Jean-Philippe Dales, Nicolas Girard, Benjamin Besse und 2 weitere

Mediastinum · 2026-10 · 10 · AB011-AB011

DOI: 10.21037/med-26-ab011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediastinum, 2026-10. Verfasst von Lara Chalabreysse und 13 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Thymic neuroendocrine tumors (TNET) are exceedingly rare, with atypical carcinoid tumors representing the most common subtype. The current WHO classification has introduced a new category, TNET G3, as the counterpart in digestive system. Here, we described the clinicopathological characteristics and survival outcomes of TNETs, with a particular focus on TNET G3. METHODS: This retrospective multicenter study included 100 patients with TNET identified from the French RYTHMIC database between 2002 and 2025. All tumors were reviewed by two expert pathologists according to the current WHO classification and staged using Masaoka Koga and pTNM (9th edition) classifications. TNET G3 were defined by an increased mitotic count (>10 mitosis/2 mm(2)) and/or a high proliferative index (Ki67 >30%). Immunohistochemical analyses were performed using a panel of antibodies including TTF1, PAX8, OTP, Rb, p53, DAXX and ATRX. RESULTS: According to the WHO classification, 4 patients were diagnosed with typical carcinoids (TNET G1), 68 atypical carcinoids (TNET G2), 21 TNET G3, 3 large cell neuroendocrine carcinomas and 4 small cell carcinomas. TNETs (G1, G2 and G3) occurred predominantly in men (76%), with a median age of 52 years at diagnosis and 19 patients had MEN1 syndrome. Among the 99 patients evaluable for overall survival, 43 deaths occurred after a median follow-up of 7.8 years (95% CI: 6.1–10.4). The median overall survival was 8.9 years (95% CI: 7.7–13.4). The 3-year survival rates for TNET G1/G2, TNET G3 and neuroendocrine carcinomas, were 86.3% (95% CI: 77.8–95.6), 81.8% (95% CI: 65.2–100) and 38.1% (95% CI: 13.7–100), respectively. Among the 21 TNET G3, 11 presented with advanced stage disease at diagnosis [1 TNM stage III, 2 stage IVa (N1) and 8 stages IVb (N2)]. All G3 tumors were negative for OTP and TTF1, whereas 14 expressed PAX8. All cases showed preserved Rb expression and wild-type p53 staining, together with ATRX and DAXX expression. CONCLUSIONS: TNET are predominantly atypical carcinoid tumors (NET G2) but include a relatively high proportion of the newly recognized NET G3 subtype, which is associated with a poorer prognosis

Zitieren

APA

Chalabreysse, L., Megherbi, A., Hofman, V., Cros, J., Sizaret, D., Millière, A., Montpreville, V. D., Piton, N., Dubois, R., Dales, J., Girard, N., Besse, B., Molina, T. J., & Mansuet-Lupo, A. (2026). AB011. Clinicopathological characteristics of thymic neuroendocrine tumors from the French RYTHMIC Network: focus on the newly defined G3 subtype. Mediastinum, 10, AB011-AB011. https://doi.org/10.21037/med-26-ab011

Vancouver

Chalabreysse L, Megherbi A, Hofman V, Cros J, Sizaret D, Millière A, et al. AB011. Clinicopathological characteristics of thymic neuroendocrine tumors from the French RYTHMIC Network: focus on the newly defined G3 subtype. Mediastinum. 2026;10:AB011-AB011. doi:10.21037/med-26-ab011

BibTeX
@article{Chalabreysse2026,
  author = {Chalabreysse, Lara and Megherbi, Alexandre and Hofman, Véronique and Cros, Jérome and Sizaret, Damien and Millière, Alice and Montpreville, Vincent de and Piton, Nicolas and Dubois, Romain and Dales, Jean-Philippe and Girard, Nicolas and Besse, Benjamin and Molina, Thierry Jo and Mansuet-Lupo, Audrey},
  title = {AB011. Clinicopathological characteristics of thymic neuroendocrine tumors from the French RYTHMIC Network: focus on the newly defined G3 subtype},
  journal = {Mediastinum},
  year = {2026},
  volume = {10},
  pages = {AB011--AB011},
  doi = {10.21037/med-26-ab011}
}
Kostenlos starten →